SG11201906627YA - Tetrahydroquinoline derivatives as p2x7 receptor antagonists - Google Patents

Tetrahydroquinoline derivatives as p2x7 receptor antagonists

Info

Publication number
SG11201906627YA
SG11201906627YA SG11201906627YA SG11201906627YA SG11201906627YA SG 11201906627Y A SG11201906627Y A SG 11201906627YA SG 11201906627Y A SG11201906627Y A SG 11201906627YA SG 11201906627Y A SG11201906627Y A SG 11201906627YA SG 11201906627Y A SG11201906627Y A SG 11201906627YA
Authority
SG
Singapore
Prior art keywords
co7d
international
shi
pharma
meieki
Prior art date
Application number
SG11201906627YA
Inventor
Hirohide Noguchi
Yoshimasa Arano
Kazuo Ando
Kazuki Toyoshima
Toshihiko Sone
Koki Matsubara
Original Assignee
Raqualia Pharma Inc
Asahi Kasei Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Raqualia Pharma Inc, Asahi Kasei Pharma Corp filed Critical Raqualia Pharma Inc
Publication of SG11201906627YA publication Critical patent/SG11201906627YA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4747—Quinolines; Isoquinolines spiro-condensed
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/04—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms
    • C07D215/06—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to the ring carbon atoms having only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Quinoline Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 20 September 2018 (20.09.2018) WIP0 I PCT omit IIl °nolo mu im im ono iflo (10) International Publication Number WO 2018/168818 Al (51) International Patent Classification: C07D 215/48 (2006.01) A61P 37/00 (2006.01) A61K 31/47 (2006.01) A61P 43/00 (2006.01) A61K 31/4709 (2006.01) CO7D 215/20 (2006.01) A61K 31/4747 (2006.01) CO7D 221/04 (2006.01) A61K 31/5375 (2006.01) CO7D 401/06 (2006.01) A61K 31/5386 (2006.01) CO7D 401/12 (2006.01) A61P 9/06 (2006.01) CO7D 405/12 (2006.01) A61P 13/12 (2006.01) CO7D 417/12 (2006.01) A61P 19/00 (2006.01) CO7D 491/08 (2006.01) A61P 25/00 (2006.01) CO7D 498/10 (2006.01) A61P 29/00 (2006.01) COIF 7/18 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/JP2018/009627 (22) International Filing Date: 13 March 2018 (13.03.2018) (25) Filing Language: English (26) Publication Language: English = (30) Priority Data: 2017-047794 13 March 2017 (13.03.2017) JP (71) Applicants: RAQUALIA PHARMA INC. [JP/JP]; 1-21-19 Meieki Minami, Nakamura-ku, Nagoya-shi, Aichi, 4500003 (JP). ASAHI KASEI PHARMA CORPO- RATION [JP/JP]; 1-1-2 Yurakucho, Chiyoda-ku, Tokyo, 1000006 (JP). (72) Inventors: NOGUCHI, Hirohide; c/o RaQualia Phar- ma Inc., 1-21-19 Meieki Minami, Nakamura-ku, Nagoya- shi, Aichi, 4500003 (JP). ARANO, Yoshimasa; c/o RaQualia Pharma Inc., 1-21-19 Meieki Minami, Nakamu- ra-ku, Nagoya-shi, Aichi, 4500003 (JP). ANDO, Kazuo; c/o RaQualia Pharma Inc., 1-21-19 Meieki Minami, Naka- mura-ku, Nagoya-shi, Aichi, 4500003 (JP). TOYOSHI- MA, Kazuki; c/o Asahi Kasei Pharma Corporation, 1-105, Kanda Jinbocho, Chiyoda-ku, Tokyo, 1018101 (JP). SONE, Toshihiko; c/o Asahi Kasei Pharma Corporation, 1-105, Kanda Jinbocho, Chiyoda-ku, Tokyo, 1018101 (JP). MATSUBARA, Koki; c/o Asahi Kasei Pharma Corpora- tion, 1-105, Kanda Jinbocho, Chiyoda-ku, Tokyo, 1018101 (JP). (74) Agent: IWATANI, Ryo; KEIHAN Dojima Bldg. 6F, 1-31, Dojima 2-chome, Kita-ku, Osaka-shi, Osaka, 5300003 (JP). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) 1-1 0 (57) : The present invention relates to tetrahydroquinoline derivatives of the present invention or a pharmaceutically acceptable \" salt thereof or a prodrug thereof, processes for their preparation, pharmaceutical compositions containing them and their use in the 0 treatment of various disorders which are mediated via the P2X7 receptor. (54) Title: TETRAHYDROQUINOLINE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS
SG11201906627YA 2017-03-13 2018-03-13 Tetrahydroquinoline derivatives as p2x7 receptor antagonists SG11201906627YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017047794 2017-03-13
PCT/JP2018/009627 WO2018168818A1 (en) 2017-03-13 2018-03-13 Tetrahydroquinoline derivatives as p2x7 receptor antagonists

Publications (1)

Publication Number Publication Date
SG11201906627YA true SG11201906627YA (en) 2019-08-27

Family

ID=63523432

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201906627YA SG11201906627YA (en) 2017-03-13 2018-03-13 Tetrahydroquinoline derivatives as p2x7 receptor antagonists

Country Status (26)

Country Link
US (3) US11077100B2 (en)
EP (1) EP3609868B1 (en)
JP (1) JP6823196B2 (en)
KR (1) KR102285817B1 (en)
CN (1) CN110382466B (en)
AU (1) AU2018235561B2 (en)
BR (1) BR112019017333A2 (en)
CA (1) CA3049192C (en)
DK (1) DK3609868T3 (en)
ES (1) ES2963044T3 (en)
FI (1) FI3609868T3 (en)
HR (1) HRP20231682T1 (en)
HU (1) HUE064575T2 (en)
LT (1) LT3609868T (en)
MX (1) MX2019010993A (en)
MY (1) MY195013A (en)
PH (1) PH12019501418A1 (en)
PL (1) PL3609868T3 (en)
PT (1) PT3609868T (en)
RS (1) RS64995B1 (en)
RU (1) RU2724350C1 (en)
SA (1) SA519410097B1 (en)
SG (1) SG11201906627YA (en)
SI (1) SI3609868T1 (en)
TW (1) TWI764999B (en)
WO (1) WO2018168818A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY195013A (en) * 2017-03-13 2022-12-31 Raqualia Pharma Inc Tetrahydroquinoline derivatives as p2x7 receptor antagonists
CN112505213B (en) * 2019-12-19 2022-04-08 金陵药业股份有限公司 Method for detecting components of oral liquid capable of clearing heat, nourishing yin, promoting blood circulation and removing blood stasis
JPWO2022114122A1 (en) 2020-11-30 2022-06-02

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6956047B1 (en) 1995-06-06 2005-10-18 Pfizer Inc. Corticotropin releasing factor antagonists
US7067664B1 (en) 1995-06-06 2006-06-27 Pfizer Inc. Corticotropin releasing factor antagonists
WO2001007051A1 (en) 1999-07-23 2001-02-01 Merck & Co., Inc. Prenyl-protein transferase inhibitors
AP2002002583A0 (en) 2000-01-18 2002-09-30 Pfizer Prod Inc Corticotropin releasing factor antagonists.
NZ520075A (en) 2000-02-04 2004-02-27 Pfizer Prod Inc Heterocyclic amide derivatives
GB0312368D0 (en) * 2003-05-30 2003-07-02 Univ Aston Novel ureido- and amido-pyrazolone derivatives
GB0312609D0 (en) * 2003-06-02 2003-07-09 Astrazeneca Ab Novel compounds
SE0302139D0 (en) * 2003-07-28 2003-07-28 Astrazeneca Ab Novel compounds
AU2005206571B8 (en) 2004-01-23 2010-09-02 Amgen Inc. Compounds and methods of use
US20080076924A1 (en) 2006-06-30 2008-03-27 Patrick Betschmann Piperazines as P2X7 antagonists
UA100227C2 (en) * 2006-07-06 2012-12-10 Глаксо Груп Лімітед Substituted n-phenylmethyl-5-oxo-proline-2-amides as p2x7-receptor antagonists and their methods of use
JP2010518125A (en) 2007-02-12 2010-05-27 インターミューン・インコーポレーテッド Novel inhibitor of hepatitis C virus replication
GB0705882D0 (en) 2007-03-27 2007-05-02 Glaxo Group Ltd Novel compounds
WO2008124153A1 (en) * 2007-04-10 2008-10-16 H. Lundbeck A/S Heteroaryl amide analogues as p2x7 antagonists
EP2215054B8 (en) 2007-11-13 2012-02-08 Evotec AG Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
JP2011509296A (en) 2008-01-09 2011-03-24 レノビス， インコーポレイテッド Amide derivatives as ion channel ligands and pharmaceutical compositions and methods using the same
MX2011012712A (en) 2009-05-29 2012-01-30 Raqualia Pharma Inc Aryl substituted carboxamide derivatives as calcium or sodium channel blockers.
AU2012288511A1 (en) 2011-07-22 2014-03-13 Actelion Pharmaceuticals Ltd Heterocyclic amide derivatives as P2X7 receptor antagonists
MX2014004979A (en) 2011-10-24 2014-10-24 Abbvie Inc Methanol derivatives as trpv3 modulators.
US9409917B2 (en) 2012-01-20 2016-08-09 Actelion Pharmaceuticals Ltd. Heterocyclic amide derivatives as P2X7 receptor antagonists
EP2846801B1 (en) 2012-05-09 2017-04-05 Merck Sharp & Dohme Corp. Pyridine cgrp receptor antagonists
WO2014025651A1 (en) 2012-08-06 2014-02-13 Amgen Inc. Chroman derivatives as trpm8 inhibitors
TWI598325B (en) * 2012-10-12 2017-09-11 Ｈ 朗德貝克公司 Benzamides
AR094053A1 (en) * 2012-12-18 2015-07-08 Actelion Pharmaceuticals Ltd DERIVATIVES OF INDOL CARBOXAMIDE AS ANTAGONISTS OF THE P2X RECEIVER
CN104918617B (en) 2013-01-22 2017-05-10 埃科特莱茵药品有限公司 Heterocyclic amide derivatives as p2x7 receptor antagonists
ES2616883T3 (en) 2013-01-22 2017-06-14 Actelion Pharmaceuticals Ltd. Heterocyclic amide derivatives as P2X7 receptor antagonists
JO3773B1 (en) 2013-03-14 2021-01-31 Janssen Pharmaceutica Nv P2x7 modulators
EP3152192A1 (en) 2014-06-05 2017-04-12 Merck Patent GmbH Novel quinoline derivatives and their use in neurodegenerative diseases
RU2017105133A (en) 2014-07-31 2018-08-28 Мерк Патент Гмбх INDOLYSINE DERIVATIVES THAT USE FOR NEURODEGENERATIVE DISEASES
EA201790600A1 (en) 2014-09-12 2017-07-31 Янссен Фармацевтика Нв MODULATING P2X7 N-ACYL TRIAZOLOPIRASINS
MY195013A (en) * 2017-03-13 2022-12-31 Raqualia Pharma Inc Tetrahydroquinoline derivatives as p2x7 receptor antagonists

Also Published As

Publication number Publication date
JP2020514371A (en) 2020-05-21
ES2963044T3 (en) 2024-03-25
US20200405706A1 (en) 2020-12-31
US11439633B2 (en) 2022-09-13
CA3049192A1 (en) 2018-09-20
EP3609868A4 (en) 2020-12-16
US20210085667A1 (en) 2021-03-25
FI3609868T3 (en) 2023-11-22
RS64995B1 (en) 2024-01-31
AU2018235561A1 (en) 2019-08-22
KR102285817B1 (en) 2021-08-05
AU2018235561B2 (en) 2020-06-18
CN110382466B (en) 2023-01-31
WO2018168818A1 (en) 2018-09-20
TW201837020A (en) 2018-10-16
SA519410097B1 (en) 2022-09-14
RU2724350C1 (en) 2020-06-23
PH12019501418A1 (en) 2020-02-10
MY195013A (en) 2022-12-31
JP6823196B2 (en) 2021-01-27
BR112019017333A2 (en) 2020-03-31
SI3609868T1 (en) 2024-03-29
LT3609868T (en) 2023-12-11
CN110382466A (en) 2019-10-25
US20230149382A1 (en) 2023-05-18
HRP20231682T1 (en) 2024-03-29
TWI764999B (en) 2022-05-21
US11077100B2 (en) 2021-08-03
CA3049192C (en) 2022-10-25
PL3609868T3 (en) 2024-04-02
HUE064575T2 (en) 2024-04-28
KR20190129083A (en) 2019-11-19
EP3609868B1 (en) 2023-10-18
PT3609868T (en) 2023-12-18
EP3609868A1 (en) 2020-02-19
MX2019010993A (en) 2019-10-17
DK3609868T3 (en) 2023-11-27

Similar Documents

Publication Publication Date Title
SG11201908740VA (en) Sustained release delivery systems comprising traceless linkers
SG11201907840RA (en) Fused imidazo-piperidine jak inhibitors
SG11201906883SA (en) Methods for the administration of certain vmat2 inhibitors
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201906436VA (en) Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same
SG11201810628XA (en) Nasal pharmaceutical compositions with a porous excipient
SG11201808566WA (en) Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide
SG11201408251SA (en) A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota
SG11201806750WA (en) Substituted 1,2,3-triazoles as nr2b-selective nmda modulators
SG11201906627YA (en) Tetrahydroquinoline derivatives as p2x7 receptor antagonists
SG11201408617PA (en) Bifluorodioxalane-amino-benzimidazole kinase inhibitors for the treatment of cancer, autoimmuneinflammation and cns disorders
SG11201908517XA (en) Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders
SG11201804123VA (en) Modulators of kv3 channels to treat pain
SG11201407402TA (en) Carbazole-containing sulfonamides as cryptochrome modulators
SG11201809172WA (en) Crystalline forms of n-[2-(3-hydroxy-3-methylbutyl)-6-(2-hydroxypropan-2-yl)-2h-indazol-5-yl]-6-(trifluoromethyl)pyridine-2-carboxamide
SG11201909615YA (en) Salt of an aminopyridine derivative compound, a crystalline form thereof, and a process for preparing the same
SG11201807540UA (en) Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis
SG11201809702SA (en) Benzenesulfonamide compounds and their use as therapeutic agents
SG11201901850XA (en) Dopamine-b-hydroxylase inhibitors
SG11201804050QA (en) A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
SG11201908660RA (en) N-substituted indole derivatives
SG11201809671PA (en) Imidazolone compounds as human neutrophil elastase inhibitors
SG11201901477PA (en) Compound for use in the treatment of neurogenic orthostatic hypotension
SG11201907217RA (en) Pharmaceutical combinations for treating cancer
SG11201810123SA (en) Treatment of intrahepatic cholestatic diseases